Image Analysis Group (IAG), a leader in clinical trial imaging and AI-driven biomarker solutions, is expanding its footprint in the United States with the inauguration of a new office in Cambridge, Massachusetts. This strategic move places IAG in the heart of the Boston-area biotech hub, facilitating closer collaboration with pharmaceutical and biotechnology companies. The new location is set to enhance IAG’s ability to support clinical trials in the region by providing localized support, strengthening partnerships, and fostering innovation in various therapeutic areas, including oncology, neuro-oncology, and immunology.
The Cambridge office is poised to play a crucial role in IAG’s operations, especially in the management of Phase I–III clinical trials and image-intensive development programs. This expansion aligns with IAG’s commitment to offering end-to-end imaging services, such as clinical trial design consultation, optimization of imaging protocols, and centralized image analysis compliant with regulatory standards. Additionally, the company plans to generate local employment opportunities, with an emphasis on hiring in clinical imaging operations, data science, regulatory support, and business development over the next year or two.
By establishing a presence in the Boston life sciences ecosystem, IAG aims to enhance its collaborative efforts with biotechnology firms, pharmaceutical companies, academic institutions, and clinical research centers. This will bolster the company’s ability to provide standardized imaging protocols, centralized data harmonization, and consistent imaging analysis for international trials. IAG’s global operations span North America, Europe, and Asia-Pacific, working with a diverse range of pharmaceutical, biotechnology, and medtech organizations as well as contract research organizations (CROs) on multi-center studies.
Founded in 2007 and based in London, IAG operates as an imaging Clinical Research Organization (iCRO), supporting clinical trials with imaging-based endpoints across multiple disease areas, including inflammatory diseases, musculoskeletal disorders, and rare diseases. The company’s DYNAMIKA™ platform integrates AI-driven image analysis with centralized quality control and regulatory-compliant reporting, ensuring real-time oversight of clinical trials.
For more information about Image Analysis Group, visit their website at www.ia-grp.com or contact them via email at [email protected]. Press inquiries can be directed to Marie Fussell at +1 267-857-8638 or [email protected].
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.